In: Cancer Immunology, Immunotherapy, 2015, vol. 64, no. 8, p. 1033-1046
|
In: Oecologia, 2015, vol. 177, no. 1, p. 213-221
|
In: Cellular and Molecular Life Sciences, 2015, vol. 72, no. 7, p. 1231-1248
|
In: Glycobiology, 2018, vol. 28, no. 9, p. 640-647
|
In: Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, vol. 388, no. 12, p. 1283-1292
|
In: Glycobiology, 2018, vol. 28, no. 9, p. 638-639
|
In: Glycobiology, 2016, vol. 26, no. 2, p. 111-128
|
In: International Journal of Molecular Sciences, 2020, vol. 21, no. 12, p. 4441
In recent years, immunotherapy has become the most promising therapy for a variety of cancer types. The development of immune checkpoint blockade (ICB) therapies, the adoptive transfer of tumor-specific T cells (adoptive cell therapy (ACT)) or the generation of T cells engineered with chimeric antigen receptors (CAR) have been successfully applied to elicit durable immunological responses in...
|
In: European Journal of Pharmaceutics and Biopharmaceutics, 2019, vol. 139, p. 253–261
Resiquimod (R848), a member of the imidazoquinoline family, is a Toll-like receptor 7/8 agonist with high potency for cancer immunotherapy. However, tolerance induction and adverse effects limit its development as a drug. Encapsulation in a polymer matrix can circumvent these limitations, as shown in our formerly published approach where R848 was loaded into polylactic acid (PLA)-based...
|
In: Cancer Immunology, Immunotherapy, 2014, vol. 63, no. 9, p. 925-938
|